Suppr超能文献

2021 年世卫组织中枢神经系统肿瘤分类:概述。

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.

机构信息

Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.

Department of Pathology, University of California San Francisco, San Francisco, California, USA.

出版信息

Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.

Abstract

The fifth edition of the WHO Classification of Tumors of the Central Nervous System (CNS), published in 2021, is the sixth version of the international standard for the classification of brain and spinal cord tumors. Building on the 2016 updated fourth edition and the work of the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy, the 2021 fifth edition introduces major changes that advance the role of molecular diagnostics in CNS tumor classification. At the same time, it remains wedded to other established approaches to tumor diagnosis such as histology and immunohistochemistry. In doing so, the fifth edition establishes some different approaches to both CNS tumor nomenclature and grading and it emphasizes the importance of integrated diagnoses and layered reports. New tumor types and subtypes are introduced, some based on novel diagnostic technologies such as DNA methylome profiling. The present review summarizes the major general changes in the 2021 fifth edition classification and the specific changes in each taxonomic category. It is hoped that this summary provides an overview to facilitate more in-depth exploration of the entire fifth edition of the WHO Classification of Tumors of the Central Nervous System.

摘要

世界卫生组织 2021 年发布的《中枢神经系统肿瘤分类》第五版是脑和脊髓肿瘤分类的国际标准第六版。该版在 2016 年更新的第四版和中枢神经系统肿瘤分类信息分子与实用方法联盟的工作基础上,引入了重大变革,推进了分子诊断在中枢神经系统肿瘤分类中的作用。同时,它仍然依赖于肿瘤诊断的其他既定方法,如组织学和免疫组织化学。这样,第五版为中枢神经系统肿瘤命名和分级制定了一些不同的方法,并强调了综合诊断和分层报告的重要性。新版引入了新的肿瘤类型和亚型,其中一些基于新的诊断技术,如 DNA 甲基化组谱分析。本文综述了 2021 年第五版分类中的主要总体变化以及每个分类类别的具体变化。希望这份总结能提供一个概述,方便更深入地探讨整个《世界卫生组织中枢神经系统肿瘤分类》第五版。

相似文献

1
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.
2
[The 2021 WHO classification of tumours of the central nervous system].
Ann Pathol. 2022 Oct;42(5):367-382. doi: 10.1016/j.annpat.2021.11.005. Epub 2021 Dec 2.
3
World Health Organization Classification of Tumors of the Central Nervous System 5 Edition (WHO CNS5): What's new?
Indian J Pathol Microbiol. 2022 May;65(Supplement):S5-S13. doi: 10.4103/ijpm.ijpm_48_22.
4
Pediatric CNS tumors and 2021 WHO classification: what do oncologists need from pathologists?
Front Mol Neurosci. 2024 Mar 13;17:1268038. doi: 10.3389/fnmol.2024.1268038. eCollection 2024.
5
Classification and Grading of Central Nervous System Tumors According to the World Health Organization 5th Edition.
Semin Neurol. 2023 Dec;43(6):833-844. doi: 10.1055/s-0043-1776793. Epub 2023 Nov 10.
7
Major Changes in 2021 World Health Organization Classification of Central Nervous System Tumors.
Radiographics. 2022 Sep-Oct;42(5):1474-1493. doi: 10.1148/rg.210236. Epub 2022 Jul 8.
8
What Changed in CNS5? A Mini-Review on General Changes and Adult Diffuse Gliomas.
Ann Afr Med. 2024 Jul 1;23(3):255-261. doi: 10.4103/aam.aam_63_23. Epub 2024 Jul 20.
10
The WHO 2021 Classification of Central Nervous System tumours: a practical update on what neurosurgeons need to know-a minireview.
Acta Neurochir (Wien). 2022 Sep;164(9):2453-2464. doi: 10.1007/s00701-022-05301-y. Epub 2022 Jul 26.

引用本文的文献

1
Estimating Health State Utilities for IDH-Mutant Diffuse Glioma.
Pharmacoecon Open. 2025 Sep 6. doi: 10.1007/s41669-025-00603-0.
5
Combined inhibition of SHP2 overcomes adaptive resistance to type 1 BRAF inhibitors in BRAF V600E-driven high-grade glioma.
Neurooncol Adv. 2025 Aug 2;7(1):vdaf170. doi: 10.1093/noajnl/vdaf170. eCollection 2025 Jan-Dec.
6
Progenitor cells, microglia, and non-coding RNAs: Orchestrators of glioblastoma pathogenesis and therapeutic resistance.
Noncoding RNA Res. 2025 Aug 5;15:85-99. doi: 10.1016/j.ncrna.2025.07.007. eCollection 2025 Dec.
8
Neurocognitive evaluation in patients with intracranial Meningiomas: A systematic review.
Brain Spine. 2025 Aug 6;5:104383. doi: 10.1016/j.bas.2025.104383. eCollection 2025.
9
Deregulating m6A regulators leads to altered RNA biology in glioma cell lines.
bioRxiv. 2025 Aug 19:2024.10.28.620763. doi: 10.1101/2024.10.28.620763.

本文引用的文献

1
Re: International System for Human Cytogenetic or Cytogenomic Nomenclature (ISCN): Some Thoughts, by T. Liehr.
Cytogenet Genome Res. 2021;161(5):225-226. doi: 10.1159/000516655. Epub 2021 Aug 18.
3
Guidelines for human gene nomenclature.
Nat Genet. 2020 Aug;52(8):754-758. doi: 10.1038/s41588-020-0669-3.
4
CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas.
Acta Neuropathol. 2020 Sep;140(3):409-413. doi: 10.1007/s00401-020-02188-w. Epub 2020 Jul 8.
5
cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors.
Brain Pathol. 2020 Sep;30(5):863-866. doi: 10.1111/bpa.12866. Epub 2020 Jun 23.
8
Genomics Paves the Way for Better Infant Medulloblastoma Therapy.
J Clin Oncol. 2020 Jun 20;38(18):2010-2013. doi: 10.1200/JCO.20.00593. Epub 2020 Apr 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验